Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4

[1]  D. Corry,et al.  The Th2 lymphocyte products IL-4 and IL-13 rapidly induce airway hyperresponsiveness through direct effects on resident airway cells. , 2002, American journal of respiratory cell and molecular biology.

[2]  Ji Ming Wang,et al.  The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[3]  A. Sher,et al.  Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity , 2002, Nature Immunology.

[4]  S. Mitchell,et al.  Lipoxins: revelations on resolution. , 2001, Trends in pharmacological sciences.

[5]  J. Kinet,et al.  Direct effects of interleukin-13 on signaling pathways for physiological responses in cultured human airway smooth muscle cells. , 2001, American journal of respiratory and critical care medicine.

[6]  Charles N. Serhan,et al.  Lipid mediator class switching during acute inflammation: signals in resolution , 2001, Nature Immunology.

[7]  C. Serhan,et al.  Selectivity of recombinant human leukotriene D(4), leukotriene B(4), and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA(4) and regulation of vascular and inflammatory responses. , 2001, The American journal of pathology.

[8]  Stephen T Holgate,et al.  Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response , 2000, The Lancet.

[9]  K. Chung,et al.  Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response , 2000, The Lancet.

[10]  M. Sanak,et al.  Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. , 2000, The European respiratory journal.

[11]  S. Hazen,et al.  Eosinophils generate brominating oxidants in allergen-induced asthma. , 2000, The Journal of clinical investigation.

[12]  J Bousquet,et al.  Asthma. From bronchoconstriction to airways inflammation and remodeling. , 2000, American journal of respiratory and critical care medicine.

[13]  C. Serhan,et al.  Cutting Edge: Lipoxin (LX) A4 and Aspirin-Triggered 15-Epi-LXA4 Block Allergen-Induced Eosinophil Trafficking1 , 2000, The Journal of Immunology.

[14]  Hugh R. Brady,et al.  Cutting Edge: Lipoxins Rapidly Stimulate Nonphlogistic Phagocytosis of Apoptotic Neutrophils by Monocyte-Derived Macrophages1 , 2000, The Journal of Immunology.

[15]  A. Leff.  Role of leukotrienes in bronchial hyperresponsiveness and cellular responses in airways. , 2000, Thorax.

[16]  C. Serhan,et al.  Cyclooxygenase-2-Derived Prostaglandin E2 and Lipoxin A4 Accelerate Resolution of Allergic Edema in Angiostrongylus costaricensis-Infected Rats: Relationship with Concurrent Eosinophilia1 , 2000, The Journal of Immunology.

[17]  E. Silverman,et al.  Heterogeneity of therapeutic responses in asthma. , 2000, British medical bulletin.

[18]  C. Clish,et al.  Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Holgate.  The epidemic of allergy and asthma , 1999, Nature.

[20]  E. Israel,et al.  Treatment of asthma with drugs modifying the leukotriene pathway. , 1999, The New England journal of medicine.

[21]  Y. Nasuhara,et al.  Cysteinyl-leukotrienes partly mediate eotaxin-induced bronchial hyperresponsiveness and eosinophilia in IL-5 transgenic mice. , 1999, American journal of respiratory and critical care medicine.

[22]  M. Freeman,et al.  Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. , 1999, The Journal of clinical investigation.

[23]  S. Holgate,et al.  IL-5 increases expression of 5-lipoxygenase-activating protein and translocates 5-lipoxygenase to the nucleus in human blood eosinophils. , 1999, Journal of immunology.

[24]  J. Drazen,et al.  Contribution of Nitric Oxide Synthases 1, 2, and 3 to Airway Hyperresponsiveness and Inflammation in a Murine Model of Asthma , 1999, The Journal of experimental medicine.

[25]  J. Drazen,et al.  Interleukin-8 receptor modulates IgE production and B-cell expansion and trafficking in allergen-induced pulmonary inflammation. , 1999, The Journal of clinical investigation.

[26]  J. Drazen.  Leukotrienes as mediators of airway obstruction. , 1998, American journal of respiratory and critical care medicine.

[27]  T. Takano,et al.  Aspirin-triggered 15-Epi-Lipoxin A4 (LXA4) and LXA4 Stable Analogues Are Potent Inhibitors of Acute Inflammation: Evidence for Anti-inflammatory Receptors , 1997, The Journal of experimental medicine.

[28]  J. Haeggström,et al.  Lipid mediator networks in cell signaling: update and impact of cytokines 1 , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  B. Spur,et al.  Effects of lipoxin A4 on chemotaxis and degranulation of human eosinophils stimulated by platelet‐activating factor and N‐formyl‐L‐methionyl‐L‐leucyl‐L‐phenylalanine , 1994, Allergy.

[30]  B. Spur,et al.  The effects of lipoxin A4 on airway responses in asthmatic subjects. , 1992, The American review of respiratory disease.

[31]  D. Broide,et al.  Cytokines in symptomatic asthma airways. , 1992, The Journal of allergy and clinical immunology.

[32]  S. Durham,et al.  Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. , 1992, The New England journal of medicine.

[33]  V. Gant,et al.  Identification of lipoxin A4 and its relationship to the sulfidopeptide leukotrienes C4, D4, and E4 in the bronchoalveolar lavage fluids obtained from patients with selected pulmonary diseases. , 1990, The American review of respiratory disease.

[34]  K. Badr,et al.  Lipoxin A4 antagonizes cellular and in vivo actions of leukotriene D4 in rat glomerular mesangial cells: evidence for competition at a common receptor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S. Dahlén,et al.  Actions of lipoxin A4 and related compounds in smooth muscle preparations and on the microcirculation in vivo. , 1988, Advances in experimental medicine and biology.

[36]  B. Samuelsson.  FROM STUDIES OF BIOCHEMICAL MECHANISMS TO NEW BIOLOGICAL MEDIATORS: PROSTAGLANDIN ENDOPEROXIDES, THROMBOXANES, AND LEUKOTRIENES , 1984 .

[37]  B. Samuelsson.  From studies of biochemical mechanism to novel biological mediators: Prostaglandin endoperoxides, thromboxanes, and leukotriences , 1983 .